Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ADVB declined for three days, in 103 of 107 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADVB as a result. In 31 of 35 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
ADVB moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ADVB crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for ADVB entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADVB advanced for three days, in 59 of 70 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ADVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.207) is normal, around the industry mean (72.578). P/E Ratio (1.688) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ADVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
XGN broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 35 of the 39 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for XGN moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 29 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 31 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 51 cases where XGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on XGN as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +7.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 182 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 151 of 179 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.807) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
XGN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ADVB | XGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 80% |
| MACD ODDS (%) | N/A | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Advances ODDS (%) | 17 days ago 84% | 10 days ago 82% |
| Declines ODDS (%) | 1 day ago 90% | 14 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADVB’s FA Score shows that 1 FA rating(s) are green while XGN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADVB’s TA Score shows that 4 TA indicator(s) are bullish while XGN’s TA Score has 4 bullish TA indicator(s).
ADVB (@Medical Specialties) experienced а -19.12% price change this week, while XGN (@Medical Specialties) price change was +3.54% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.55%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +36.12%.
XGN is expected to report earnings on Nov 16, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XMAR | 43.79 | -0.02 | -0.03% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March (XMAR) | |||
| IBDU | 22.69 | -0.01 | -0.04% |
| iShares iBonds Dec 2029 Term Corporate ETF (IBDU) | |||
| NUKX | 30.99 | -0.18 | -0.59% |
| Nicholas Nuclear Income ETF | |||
| KGRN | 21.51 | -0.21 | -0.97% |
| KraneShares MSCI China Clean Technology Index ETF (KGRN) | |||
| PJP | 120.92 | -2.52 | -2.04% |
| Invesco Pharmaceuticals ETF (PJP) | |||
A.I.dvisor tells us that ADVB and OPK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADVB and OPK's prices will move in lockstep.
| Ticker / NAME | Correlation To ADVB | 1D Price Change % | ||
|---|---|---|---|---|
| ADVB | 100% | -2.18% | ||
| OPK - ADVB | 22% Poorly correlated | -4.35% | ||
| XGN - ADVB | 22% Poorly correlated | +2.79% | ||
| QUCY - ADVB | 21% Poorly correlated | +8.74% | ||
| BIAF - ADVB | 4% Poorly correlated | -7.05% | ||
| MDXH - ADVB | 3% Poorly correlated | +9.29% | ||
More | ||||
A.I.dvisor tells us that XGN and SHC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and SHC's prices will move in lockstep.
| Ticker / NAME | Correlation To XGN | 1D Price Change % | ||
|---|---|---|---|---|
| XGN | 100% | +2.79% | ||
| SHC - XGN | 30% Poorly correlated | +0.33% | ||
| NTRA - XGN | 28% Poorly correlated | -0.53% | ||
| QDEL - XGN | 26% Poorly correlated | +6.42% | ||
| MXCT - XGN | 25% Poorly correlated | -3.09% | ||
| GRAL - XGN | 25% Poorly correlated | +2.17% | ||
More | ||||